

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-20. (Canceled)

21. (Currently Amended) An siRNA molecule comprising a sense strand hybridized to an antisense strand, wherein the antisense strand targets a region in a 17AA site of a Wilms' tumor gene transcript, ~~and wherein the siRNA suppresses cell growth,~~ the sense strand comprises SEQ ID NO: 1, and the antisense strand comprises SEQ ID NO: 2.

22. (Previously presented) The siRNA molecule of claim 21, wherein each of the sense and antisense strands is 15 to 49 bases in length.

23. (Cancelled)

24. (Previously presented) The siRNA molecule of claim 21, wherein at least one of the sense and antisense strands has a single-stranded overhang at one end.

25. (Cancelled)

26. (Cancelled)

27. (Currently Amended) A DNA comprising a sequence that is transcribed into a sense RNA strand and an antisense RNA strand that hybridize together to form an siRNA that suppresses cell growth, wherein the antisense RNA strand targets a region in a 17AA site of a Wilms' tumor

gene transcript, the sense RNA strand comprises SEQ ID NO: 1, and the antisense RNA strand comprises SEQ ID NO: 2.

28. (Cancelled)

29. (Cancelled)

30. (Previously presented) The DNA of claim 27, wherein each of the sense and antisense RNA strands is 15 to 49 bases in length.

31. (Previously presented) The DNA of claim 27, wherein at least one of the sense and antisense RNA strands has a single-stranded overhang at one end.

32. (Cancelled)

33. (Cancelled)

34. (Currently Amended) A pair of DNAs, the first DNA comprising a sequence that is transcribed into a sense RNA strand and the second DNA comprising a sequence that is transcribed into an antisense RNA strand, wherein the sense and antisense RNA strands hybridize together to form an siRNA that suppresses cell growth, ~~and wherein~~ the antisense RNA strand targets a region in a 17 AA site of a Wilms' tumor gene transcript, the sense RNA strand comprises SEQ ID NO: 1, and the antisense RNA strand comprises SEQ ID NO: 2.

35. (Previously presented) The pair of DNAs of claim 34, wherein each of the sense and antisense RNA strands is 15 to 49 bases in length.

36. (Previously presented) The pair of DNAs of claim 34, wherein at least one of the sense and antisense RNA strands has a single-stranded overhang at one end.

37. (Cancelled)
38. (Cancelled)
39. (Previously presented) A vector comprising the DNA of claim 27.
40. (Cancelled)
41. (Cancelled)
42. (Previously presented) A vector comprising the DNA of claim 30.
43. (Previously presented) A vector comprising the DNA of claim 31.
44. (Cancelled)
45. (Cancelled)
46. (Previously presented) A pair of vectors, each vector comprising one of the DNAs of claim 34.
47. (Previously presented) The siRNA molecule of claim 21, wherein the siRNA inhibits growth of a cancer cell.
48. (Previously presented) The siRNA molecule of claim 21, wherein the siRNA induces death of a cancer cell.
49. (Previously presented) The siRNA molecule of claim 21, wherein the siRNA inhibits growth of a fibrosarcoma cell, colon cancer cell, leukemia cell, or gastric cancer cell.

50. (Previously presented) The siRNA molecule of claim 21, wherein the siRNA enhances sensitivity of a cancer cell to an anticancer agent.

51. (Previously presented) The siRNA molecule of claim 21, wherein the siRNA enhances sensitivity of a cancer cell to a cell-death-inducing agent.

52. (Previously presented) The siRNA molecule of claim 21, wherein the siRNA enhances cytochrome c release into cytoplasm of a cell.